Pub Date : 2024-11-20DOI: 10.1080/20415990.2024.2426447
Sara Salatin, Maryam Azarfarin, Afsaneh Farjami, Samin Hamidi
Cancer is increasingly being recognized as a global health issue with considerable unmet medical need. Despite the rapid progression of anticancer pharmaceuticals, there are still significant challenges for the effective management of cancer. In many circumstances, cancer cells are difficult to detect and treat. Combination of nanovesicles (NVs) and magnetic nanoparticles (MNPs), referred as magnetic nanovesicles (MNVs), is now well recognized as a potential theranostic option for improving cancer treatment outcomes and reducing adverse effects. MNVs can be used for monitoring the long-term fate and functional benefits of cancer therapy. Moreover, MNV-mediated hyperthermia mechanism has been explored as a potential technique for triggering cancer cell death, and/or controlled release of laden cargo. In this review, we focus on the unique characteristics of MNVs as a promising avenue for targeted drug delivery, diagnosis, and treatments of cancer or tumor. Moreover, we discuss critical considerations related to the issues raised in this area, which will guide future research toward better anti-cancer therapeutics for clinical applications.
{"title":"The simultaneous use of nanovesicles and magnetic nanoparticles for cancer targeting and imaging.","authors":"Sara Salatin, Maryam Azarfarin, Afsaneh Farjami, Samin Hamidi","doi":"10.1080/20415990.2024.2426447","DOIUrl":"https://doi.org/10.1080/20415990.2024.2426447","url":null,"abstract":"<p><p>Cancer is increasingly being recognized as a global health issue with considerable unmet medical need. Despite the rapid progression of anticancer pharmaceuticals, there are still significant challenges for the effective management of cancer. In many circumstances, cancer cells are difficult to detect and treat. Combination of nanovesicles (NVs) and magnetic nanoparticles (MNPs), referred as magnetic nanovesicles (MNVs), is now well recognized as a potential theranostic option for improving cancer treatment outcomes and reducing adverse effects. MNVs can be used for monitoring the long-term fate and functional benefits of cancer therapy. Moreover, MNV-mediated hyperthermia mechanism has been explored as a potential technique for triggering cancer cell death, and/or controlled release of laden cargo. In this review, we focus on the unique characteristics of MNVs as a promising avenue for targeted drug delivery, diagnosis, and treatments of cancer or tumor. Moreover, we discuss critical considerations related to the issues raised in this area, which will guide future research toward better anti-cancer therapeutics for clinical applications.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-15DOI: 10.1080/20415990.2024.2426824
Heba Mohammed Refat M Selim, Fatma Alzahraa M Gomaa, Mohammad Y Alshahrani, Radwa N Morgan, Khaled M Aboshanab
The ongoing global health crisis caused by multidrug-resistant (MDR) bacteria necessitates quick interventions to introduce new management strategies for MDR-associated infections and antimicrobial agents' resistance. Phage therapy emerges as an antibiotic substitute for its high specificity, efficacy, and safety profiles in treating MDR-associated infections. Various in vitro and in vivo studies denoted their eminent bactericidal and anti-biofilm potential. This review addresses the latest developments in phage therapy regarding their attack strategies, formulations, and administration routes. It additionally discusses and elaborates on the status of phage therapy undergoing clinical trials, and the challenges encountered in their usage, and explores prospects in phage therapy research and application.
{"title":"Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens.","authors":"Heba Mohammed Refat M Selim, Fatma Alzahraa M Gomaa, Mohammad Y Alshahrani, Radwa N Morgan, Khaled M Aboshanab","doi":"10.1080/20415990.2024.2426824","DOIUrl":"https://doi.org/10.1080/20415990.2024.2426824","url":null,"abstract":"<p><p>The ongoing global health crisis caused by multidrug-resistant (MDR) bacteria necessitates quick interventions to introduce new management strategies for MDR-associated infections and antimicrobial agents' resistance. Phage therapy emerges as an antibiotic substitute for its high specificity, efficacy, and safety profiles in treating MDR-associated infections. Various <i>in vitro</i> and <i>in vivo</i> studies denoted their eminent bactericidal and anti-biofilm potential. This review addresses the latest developments in phage therapy regarding their attack strategies, formulations, and administration routes. It additionally discusses and elaborates on the status of phage therapy undergoing clinical trials, and the challenges encountered in their usage, and explores prospects in phage therapy research and application.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-23"},"PeriodicalIF":3.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: The goal of the present work was to formulate zein-decorated rifaximin (RFX) nanosuspension to attain sustained release as well as effectiveness against Escherichia coli (E. coli).Methods: The RFX nanosuspension was fabricated by using antisolvent addition method followed by coating using hydroalcoholic zein solution. The optimized RFX-NS and RFX-NS@zein was lyophilized for further spectroscopic evaluations. In vitro antibacterial potential was elucidated using well diffusion method whereas MIC value was determined by microbroth dilution method against E. coli for RFX-NS and pure RFX.Results: Box-Behnken Design was employed to assess the effects of independent variables on quality target product profile of RFX-NS. Optimized RFX-NS depicted particle size of 193.5 ± 4.45 nm with 76.49 ± 1.71% drug content. The significant change in particle size and zeta potential confirmed the formation of zein coated RFX-NS (RFX-NS@zein). In vitro release study depicted, 96.91 ± 1.21% release of RFX from RFX-NS in 6 h whereas 97.47 ± 1.99% RFX release was observed from RFX-NS@zein at the end of 12 h. Antibacterial assay of RFX-NS and free RFX against E. coli displayed MIC value of 15.44 ± 0.01 μg/ml and 72.96 ± 0.25 μg/ml, respectively.Conclusion: The results highlighted a significance of nanosuspension for improving the solubility of RFX and its antibacterial potential against E. coli.
{"title":"Zein decorated rifaximin nanosuspension: approach for sustained release and anti-bacterial efficacy enhancement.","authors":"Atul Mourya, Mayank Handa, Kanchan Singh, Suresh Chintalapati, Jitender Madan, Rahul Shukla","doi":"10.1080/20415990.2024.2418799","DOIUrl":"https://doi.org/10.1080/20415990.2024.2418799","url":null,"abstract":"<p><p><b>Aim:</b> The goal of the present work was to formulate zein-decorated rifaximin (RFX) nanosuspension to attain sustained release as well as effectiveness against <i>Escherichia coli (E. coli)</i>.<b>Methods:</b> The RFX nanosuspension was fabricated by using antisolvent addition method followed by coating using hydroalcoholic zein solution. The optimized RFX-NS and RFX-NS@zein was lyophilized for further spectroscopic evaluations. <i>In vitro</i> antibacterial potential was elucidated using well diffusion method whereas MIC value was determined by microbroth dilution method against <i>E. coli</i> for RFX-NS and pure RFX.<b>Results:</b> Box-Behnken Design was employed to assess the effects of independent variables on quality target product profile of RFX-NS. Optimized RFX-NS depicted particle size of 193.5 ± 4.45 nm with 76.49 ± 1.71% drug content. The significant change in particle size and zeta potential confirmed the formation of zein coated RFX-NS (RFX-NS@zein). <i>In vitro</i> release study depicted, 96.91 ± 1.21% release of RFX from RFX-NS in 6 h whereas 97.47 ± 1.99% RFX release was observed from RFX-NS@zein at the end of 12 h. Antibacterial assay of RFX-NS and free RFX against <i>E. coli</i> displayed MIC value of 15.44 ± 0.01 μg/ml and 72.96 ± 0.25 μg/ml, respectively.<b>Conclusion:</b> The results highlighted a significance of nanosuspension for improving the solubility of RFX and its antibacterial potential against <i>E. coli</i>.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12DOI: 10.1080/20415990.2024.2418800
Sindi P Ndlovu, Shirley C M Motaung, Samson A Adeyemi, Philemon Ubanako, Lindokuhle M Ngema, Thierry Youmbi Fonkui, Derek Tantoh Ndinteh, Pradeep Kumar, Yahya E Choonara, Blessing A Aderibigbe
Aim: Using appropriate wound dressings is crucial when treating burn wounds to promote accelerated healing.Materials & methods: Sodium alginate (SA)-based gels containing Carboxymethyl cellulose (CMC) and Pluronic F127 were prepared. The formulations. SA/CMC/Carbopol and SA/CMC/PluronicF127 were loaded with aqueous root extract of Capparis sepiaria. The formulations were characterized using appropriate techniques.Results: The gels' viscosity was in the range of 676.33 ± 121.76 to 20.00 ± 9.78 cP and in vitro whole blood kinetics showed their capability to induce a faster clotting rate. They also supported high cell viability of 80% with cellular migration and proliferation. Their antibacterial activity was significant against most bacteria strains used in the study.Conclusion: The gels' distinct features reveal their potential application as wound dressings for burn wounds.
{"title":"Sodium alginate/carboxymethylcellulose gel formulations containing <i>Capparis sepieria</i> plant extract for wound healing.","authors":"Sindi P Ndlovu, Shirley C M Motaung, Samson A Adeyemi, Philemon Ubanako, Lindokuhle M Ngema, Thierry Youmbi Fonkui, Derek Tantoh Ndinteh, Pradeep Kumar, Yahya E Choonara, Blessing A Aderibigbe","doi":"10.1080/20415990.2024.2418800","DOIUrl":"https://doi.org/10.1080/20415990.2024.2418800","url":null,"abstract":"<p><p><b>Aim:</b> Using appropriate wound dressings is crucial when treating burn wounds to promote accelerated healing.<b>Materials & methods:</b> Sodium alginate (SA)-based gels containing Carboxymethyl cellulose (CMC) and Pluronic F127 were prepared. The formulations. SA/CMC/Carbopol and SA/CMC/PluronicF127 were loaded with aqueous root extract of <i>Capparis sepiaria</i>. The formulations were characterized using appropriate techniques.<b>Results:</b> The gels' viscosity was in the range of 676.33 ± 121.76 to 20.00 ± 9.78 cP and <i>in vitro</i> whole blood kinetics showed their capability to induce a faster clotting rate. They also supported high cell viability of 80% with cellular migration and proliferation. Their antibacterial activity was significant against most bacteria strains used in the study.<b>Conclusion:</b> The gels' distinct features reveal their potential application as wound dressings for burn wounds.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-17"},"PeriodicalIF":3.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12DOI: 10.1080/20415990.2024.2421155
Ariel Gustavo Garro, Soledad Ravetti, Sofía Gisella Brignone, Agustín Luna, Natalia Angel Villegas, Agustina Gaitán, Santiago Daniel Palma
Cannabidiol (CBD), extracted from Cannabis sativa L., holds therapeutic promise without inducing psychoactive effects seen with Δ9-tetrahydrocannabinol. Its interaction with the endocannabinoid system plays a pivotal role in regulating mood, pain perception and immune function. Nevertheless, CBD encounters hurdles in clinical application due to its poor bioavailability and water solubility. To overcome these limitations, researchers are exploring microencapsulation techniques, which involve encapsulating CBD within protective matrices. This comprehensive review offers insights into various microencapsulation methods for CBD, scrutinizing their advantages, limitations and implications for formulation optimization. By elucidating the potential of microencapsulation, this review underscores its promise in refining CBD therapy and addressing challenges associated with administration.
{"title":"Microencapsulation techniques for developing cannabidiol formulations: a review.","authors":"Ariel Gustavo Garro, Soledad Ravetti, Sofía Gisella Brignone, Agustín Luna, Natalia Angel Villegas, Agustina Gaitán, Santiago Daniel Palma","doi":"10.1080/20415990.2024.2421155","DOIUrl":"https://doi.org/10.1080/20415990.2024.2421155","url":null,"abstract":"<p><p>Cannabidiol (CBD), extracted from <i>Cannabis sativa</i> L., holds therapeutic promise without inducing psychoactive effects seen with Δ9-tetrahydrocannabinol. Its interaction with the endocannabinoid system plays a pivotal role in regulating mood, pain perception and immune function. Nevertheless, CBD encounters hurdles in clinical application due to its poor bioavailability and water solubility. To overcome these limitations, researchers are exploring microencapsulation techniques, which involve encapsulating CBD within protective matrices. This comprehensive review offers insights into various microencapsulation methods for CBD, scrutinizing their advantages, limitations and implications for formulation optimization. By elucidating the potential of microencapsulation, this review underscores its promise in refining CBD therapy and addressing challenges associated with administration.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: Laboratory scale-up of artemisinin-loaded emulgel (ART-emulgel) was carried out and characterized for therapeutic performance in osteoarthritis (OA).Materials & methods: The solubility of ART in various oils, surfactants and co-surfactants were screened for construction of pseudo ternary phase diagram (TPD), followed by scale-up of artemisinin loaded nanoemulsion (ART-NE). ART-NE was amalgamated with Carbopol Ultrez 10-NF to prepare ART-emulgel that was later characterized in vitro and in vivo to analyze therapeutic efficacy in monosodium-iodoacetate (MIA) induced knee OA.Results: The droplet diameter of ART-NE was estimated to be 104.3 ± 2.593 nm with a polydispersity index of 0.245 ± 0.019 in addition to ζ-potential of 0.434 ± 0.028 mV. Steady-state flux and permeability coefficient for ART-emulgel were estimated to be 0.651 ± 0.031 µg.cm2/h and 0.245 ± 0.011 cm/h, respectively. ART-emulgel demonstrated 43.18% reduction in COX-2 level; 52.28% drop in IL-1β, and 88.78% alleviation of Tumor Necrosis Factor-α (TNF-α) level when compared with monosodium-iodoacetate induced OA rats. ART-emulgel and injectable ART (intra-articular; I.A) portrayed minor synovial erosion compared with blank and diclofenac emulgel. Histopathological evidences indicated restoration of cartilage integrity followed by reduction of OARSI scores in ART-emulgel when compared with disease control animals.Conclusion: ART-emulgel is a potential dosage form for translating into a clinically viable product for the management of OA.
{"title":"Artemisinin emulgel ameliorates cartilage degradation in knee osteoarthritis: <i>in vitro</i> and <i>in vivo</i> studies.","authors":"Samiksha Thote, Atul Mourya, Shristi Arya, Hoshiyar Singh, Prashanth Kumar, Santosh Kumar Guru, Jitender Madan","doi":"10.1080/20415990.2024.2418281","DOIUrl":"https://doi.org/10.1080/20415990.2024.2418281","url":null,"abstract":"<p><p><b>Aim:</b> Laboratory scale-up of artemisinin-loaded emulgel (ART-emulgel) was carried out and characterized for therapeutic performance in osteoarthritis (OA).<b>Materials & methods:</b> The solubility of ART in various oils, surfactants and co-surfactants were screened for construction of pseudo ternary phase diagram (TPD), followed by scale-up of artemisinin loaded nanoemulsion (ART-NE). ART-NE was amalgamated with Carbopol Ultrez 10-NF to prepare ART-emulgel that was later characterized <i>in vitro</i> and <i>in vivo</i> to analyze therapeutic efficacy in monosodium-iodoacetate (MIA) induced knee OA.<b>Results:</b> The droplet diameter of ART-NE was estimated to be 104.3 ± 2.593 nm with a polydispersity index of 0.245 ± 0.019 in addition to ζ-potential of 0.434 ± 0.028 mV. Steady-state flux and permeability coefficient for ART-emulgel were estimated to be 0.651 ± 0.031 µg.cm<sup>2</sup>/h and 0.245 ± 0.011 cm/h, respectively. ART-emulgel demonstrated 43.18% reduction in COX-2 level; 52.28% drop in IL-1β, and 88.78% alleviation of Tumor Necrosis Factor-α (TNF-α) level when compared with monosodium-iodoacetate induced OA rats. ART-emulgel and injectable ART (intra-articular; I.A) portrayed minor synovial erosion compared with blank and diclofenac emulgel. Histopathological evidences indicated restoration of cartilage integrity followed by reduction of OARSI scores in ART-emulgel when compared with disease control animals.<b>Conclusion:</b> ART-emulgel is a potential dosage form for translating into a clinically viable product for the management of OA.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-17"},"PeriodicalIF":3.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Glioblastoma multiforme (GBM) is one of the most common and malignant brain tumors, with a high prevalence in elderly population. Most chemotherapeutic agents fail to reach the tumor site due to various challenges. However, smart nanocarriers have demonstrated excellent drug-loading capabilities, enabling them to cross the blood brain tumor barrier for the GBM treatment. Surface modification of nanocarriers has significantly enhanced their potential for targeting therapeutics. Moreover, recent innovations in drug therapies, such as the incorporation of theranostic agents in nanocarriers and antibody-drug conjugates, have offered newer insights for both diagnosis and treatment. This review focuses on recent advances in new therapeutic interventions for GBM, with an emphasis on the nanotheranostics systems to maximize therapeutic and diagnostic outcomes.
{"title":"Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.","authors":"Ashish Dhiman, Dhwani Rana, Derajram Benival, Kalpna Garkhal","doi":"10.1080/20415990.2024.2415281","DOIUrl":"https://doi.org/10.1080/20415990.2024.2415281","url":null,"abstract":"<p><p>Glioblastoma multiforme (GBM) is one of the most common and malignant brain tumors, with a high prevalence in elderly population. Most chemotherapeutic agents fail to reach the tumor site due to various challenges. However, smart nanocarriers have demonstrated excellent drug-loading capabilities, enabling them to cross the blood brain tumor barrier for the GBM treatment. Surface modification of nanocarriers has significantly enhanced their potential for targeting therapeutics. Moreover, recent innovations in drug therapies, such as the incorporation of theranostic agents in nanocarriers and antibody-drug conjugates, have offered newer insights for both diagnosis and treatment. This review focuses on recent advances in new therapeutic interventions for GBM, with an emphasis on the nanotheranostics systems to maximize therapeutic and diagnostic outcomes.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-29"},"PeriodicalIF":3.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-21DOI: 10.1080/20415990.2024.2408218
Pravin Patil, Mrunal Rahangdale, Krutika Sawant
Aim: The study explores glycerosomes as effective vesicular systems for transdermal delivery of atorvastatin (ATO) to overcome drawbacks related to its oral administration.Methodology: The objectives of this study were to formulate, by thin-film hydration method, optimize using definitive screening design and evaluate ATO-loaded glycerosomes (ATOG) which were then incorporated into patch followed by the evaluation of glycerosomes containing different concentration of glycerol.Results & discussion: Vesicle size, Polydispersity index (PDI), zeta potential, entrapment efficiency and loading capacity of spherical ATOG (0-30%w/w) showed 137.3-192d.nm, 0.292-0.403, -3.81 to-6.76mV, 80.03-92.77% and 5.80-6.40%, respectively. In-vitro release study showed sustained release, increased skin permeability and better cell viability than pure drug. ATOG patches showed greater skin permeability than pure drug and ATO-liposomal patches.Conclusion: The study concludes that ATOGs are promising for effective transdermal delivery.
目的:本研究探讨了甘油囊作为阿托伐他汀(ATO)透皮给药的有效囊泡系统,以克服口服给药的相关缺点:本研究的目的是通过薄膜水合法配制、使用确定性筛选设计进行优化并评估负载 ATO 的甘油囊(ATOG),然后将其纳入贴片,接着评估含有不同浓度甘油的甘油囊:球形 ATOG(0-30%w/w)的囊泡大小、多分散指数(PDI)、ZETA电位、夹持效率和负载能力分别为 137.3-192d.nm、0.292-0.403、-3.81-6.76mV、80.03-92.77% 和 5.80-6.40%。体外释放研究显示,与纯药物相比,ATOG 贴片具有持续释放、皮肤渗透性更强和细胞存活率更高的特点。ATOG 贴片的皮肤渗透性高于纯药物和 ATO 脂质体贴片:该研究得出结论,ATOGs 有望实现有效的透皮给药。
{"title":"Atorvastatin loaded glycerosomal patch as an effective transdermal drug delivery: optimization and evaluation.","authors":"Pravin Patil, Mrunal Rahangdale, Krutika Sawant","doi":"10.1080/20415990.2024.2408218","DOIUrl":"https://doi.org/10.1080/20415990.2024.2408218","url":null,"abstract":"<p><p><b>Aim:</b> The study explores glycerosomes as effective vesicular systems for transdermal delivery of atorvastatin (ATO) to overcome drawbacks related to its oral administration.<b>Methodology:</b> The objectives of this study were to formulate, by thin-film hydration method, optimize using definitive screening design and evaluate ATO-loaded glycerosomes (ATOG) which were then incorporated into patch followed by the evaluation of glycerosomes containing different concentration of glycerol.<b>Results & discussion:</b> Vesicle size, Polydispersity index (PDI), zeta potential, entrapment efficiency and loading capacity of spherical ATOG (0-30%w/w) showed 137.3-192d.nm, 0.292-0.403, -3.81 to-6.76mV, 80.03-92.77% and 5.80-6.40%, respectively. <i>In-vitro</i> release study showed sustained release, increased skin permeability and better cell viability than pure drug. ATOG patches showed greater skin permeability than pure drug and ATO-liposomal patches.<b>Conclusion:</b> The study concludes that ATOGs are promising for effective transdermal delivery.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-20"},"PeriodicalIF":3.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1080/20415990.2024.2414732
Peter Timmins
{"title":"Industry Update: the latest developments in the field of therapeutic delivery, July 2024.","authors":"Peter Timmins","doi":"10.1080/20415990.2024.2414732","DOIUrl":"https://doi.org/10.1080/20415990.2024.2414732","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-16DOI: 10.1080/20415990.2024.2411943
Janhavi Bhavsar, Kaustubh Kasture, Bhagyashree V Salvi, Pravin Shende
An established view in genetic engineering dictates an increase in the discovery of therapeutic peptides to enable the treatment of multiple diseases. The use of hypodermic needle for delivery of proteins and peptides occurs due to the hydrophilic nature, sensitivity toward proteolytic enzymes and high molecular weight. The non-invasive nature of the transdermal delivery technique offers multiple advantages over the invasive route to release drugs directly into the systemic circulation to enhance bioavailability, better patient compliance, reduced toxicity and local irritability. The transdermal route seems highly desirable from the pharmaco-therapeutic and patient compliance point of view, however, the lipophilic barrier of skin restricts the application. The use of several techniques like electrical methods (iontophoresis, sonophoresis etc.), chemical penetration enhancers (e.g. protease inhibitors, penetration enhancers, etc.) and nanocarriers (dendrimers, lipid nanocapsules, etc.) are utilized to improve the passage of drug molecules across the biomembranes. Additionally, such clinical interventions facilitate the physicochemical characteristics of peptides, to enable effective preservation, conveyance and release of therapeutic agents. Moreover, strategies ensure the attainment of the intended targets and enhance treatment outcomes for multiple diseases. This review article focuses on the techniques of peptide transportation across the skin to advance the delivery approaches and therapeutic efficiency.
{"title":"Strategies for transportation of peptides across the skin for treatment of multiple diseases.","authors":"Janhavi Bhavsar, Kaustubh Kasture, Bhagyashree V Salvi, Pravin Shende","doi":"10.1080/20415990.2024.2411943","DOIUrl":"https://doi.org/10.1080/20415990.2024.2411943","url":null,"abstract":"<p><p>An established view in genetic engineering dictates an increase in the discovery of therapeutic peptides to enable the treatment of multiple diseases. The use of hypodermic needle for delivery of proteins and peptides occurs due to the hydrophilic nature, sensitivity toward proteolytic enzymes and high molecular weight. The non-invasive nature of the transdermal delivery technique offers multiple advantages over the invasive route to release drugs directly into the systemic circulation to enhance bioavailability, better patient compliance, reduced toxicity and local irritability. The transdermal route seems highly desirable from the pharmaco-therapeutic and patient compliance point of view, however, the lipophilic barrier of skin restricts the application. The use of several techniques like electrical methods (iontophoresis, sonophoresis etc.), chemical penetration enhancers (e.g. protease inhibitors, penetration enhancers, etc.) and nanocarriers (dendrimers, lipid nanocapsules, etc.) are utilized to improve the passage of drug molecules across the biomembranes. Additionally, such clinical interventions facilitate the physicochemical characteristics of peptides, to enable effective preservation, conveyance and release of therapeutic agents. Moreover, strategies ensure the attainment of the intended targets and enhance treatment outcomes for multiple diseases. This review article focuses on the techniques of peptide transportation across the skin to advance the delivery approaches and therapeutic efficiency.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-24"},"PeriodicalIF":3.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}